BETHESDA, Md., June 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company focused on the development and commercialization of next-generation antibodies for the treatment of cancer, today announced that Christian Itin, Ph.D., Micromet's President and Chief Executive Officer, will present a corporate overview at three upcoming investor conferences:
Jefferies 2010 Global Life Sciences Conference
Wednesday, June 9, at 2 PM ET
Grand Hyatt, New York City
9th Annual Needham Healthcare Conference
Thursday, June 10 at 8:40 AM ET
New York Palace Hotel, New York City
31st Annual Goldman Sachs Global Healthcare Conference
Wednesday, June 16 at 11 AM ET
Century Plaza Hyatt Regency, Los Angeles
The presentations will be webcast live and may be accessed by visiting the Micromet website at www.micromet-inc.com. A replay of the webcasts will also be available on the Company's website.
About Micromet, Inc.
Micromet, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibody-based therapies for the treatment of cancer. Its product development pipeline includes novel antibodies generated with its proprietary BiTE® technology, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet has collaborations with a number of leading pharmaceutical and biotechnology companies, including sanofi-aventis, Bayer Schering Pharma, Merck Serono, Boehringer Ingelheim, MedImmune and Nycomed. Additional information can be found at www.micromet-inc.com.
SOURCE Micromet, Inc.